Citing personal reasons, Michael Dey resigned his new post asvice president of pharmaceutical development at
Procyte Corp. of Kirkland, Wash. Dey's responsibilities will beassumed temporarily by ProCyte's Ron Warner until areplacement is named.
Deciding that "a change in management was in the bestinterest of the company," the board of directors of Belmac Corp.has decided to replace its president and chief executive officer,Michael Harshbarger. Harshbarger had been CEO of the Tampa,Fla., company for five months. He will remain a director.
Alpha 1 Biomedicals Inc. of Bethesda, Md., has appointed Martin Roseas senior vice president of clinical and regulatory affairs. Rose hadbeen the senior director of government affairs at Genentech Inc.
Donald Murfin has joined the board of directors of Seattle-basedTargeted Genetics Corp. Murfin is a general partner in Chemicals andMaterials Enterprise Associates, a venture capital fund affiliated withNew Enterprise Associates.
Renato Fuchs has joined Chiron Corp. of Emeryville, Calif., as asenior vice president. Fuchs will be responsible for worldwidemanufacturing and process development for all of Chiron'stherapeutics. He had been senior vice president ofpharmaceutical development at Centocor Inc., where hemanaged process development and transfer productiontechnology for Centocor's St. Louis, Mo., and Leiden,Netherlands, manufacturing facilities.
(c) 1997 American Health Consultants. All rights reserved.